{"id":8774,"date":"2025-09-20T23:45:00","date_gmt":"2025-09-20T23:45:00","guid":{"rendered":"https:\/\/ksabuild.me\/india-diabetes-drugs-market-to-reach-usd-2-09-billion-by-2030-oral-drug-segments-expected-to-drive-growth\/"},"modified":"2025-09-21T14:27:28","modified_gmt":"2025-09-21T14:27:28","slug":"india-diabetes-drugs-market-to-reach-usd-2-09-billion-by-2030-oral-drug-segments-expected-to-drive-growth","status":"publish","type":"post","link":"https:\/\/ksabuild.me\/en\/india-diabetes-drugs-market-to-reach-usd-2-09-billion-by-2030-oral-drug-segments-expected-to-drive-growth\/","title":{"rendered":"India Diabetes Drugs Market to Reach USD 2.09 Billion by 2030; Oral Drug Segments Expected to Drive Growth"},"content":{"rendered":"


\n<\/p>\n

Introduction<\/span><\/b>\u00a0<\/span><\/p>\n

India diabetes drugs market is showing steady growth, underpinned by rising diabetes incidence, shifting treatment patterns, and increasing access to healthcare. According to Mordor Intelligence, the <\/span>India diabetes drugs market size<\/span><\/a> is estimated at <\/span>USD 1.76 billion in 2025 and<\/span><\/b> is projected to grow to <\/span>USD 2.09 billion by 2030<\/span><\/b>, at a CAGR of about 3.5% during the forecast period.\u00a0<\/span>\u00a0<\/span><\/p>\n

This growth reflects multiple factors: growing awareness of diabetes (especially type-2), the push from the government for affordable drug access, increasing use of newer drug classes, and pressure from generics. These trends are not only shaping market value, but also influencing market share, competitive behaviour, and segmentation in meaningful ways.<\/span>\u00a0<\/span><\/p>\n

Key Trends in India Diabetes Drugs Market<\/span><\/b>\u00a0<\/span><\/p>\n

Growing Use of Oral Anti-Diabetic Drugs<\/span><\/b>\u00a0<\/span><\/p>\n

Oral anti-diabetic drugs remain a central pillar of the India diabetes drugs market. They maintain the largest share in many segments due to ease of administration, familiarity among physicians, and cost advantages. Among oral classes, <\/span>Biguanides<\/span><\/i> are leading, followed by sulfonylureas and increasingly by SGLT-2 inhibitors. The SGLT-2 inhibitors class is expected to register one of the fastest growth rates through the forecast period.\u00a0<\/span>\u00a0<\/span><\/p>\n

Rising Demand for Newer Drug Classes<\/span><\/b>\u00a0<\/span><\/p>\n

While traditional oral classes dominate, there is rising demand for newer classes and combinations aimed at improving outcomes, reducing side effects, and addressing comorbid conditions. Examples include fixed-dose combinations, SGLT-2 inhibitors, DPP-4 inhibitors etc. Patent expiries also open pathways for generics in some of these newer classes.\u00a0<\/span>\u00a0<\/span><\/p>\n

Generic Competition and Policy Interventions<\/span><\/b>\u00a0<\/span><\/p>\n

Generic manufacturers have become more active, both in introducing off-patent versions and in producing trade generics. Government policies (such as pricing controls, support for generics, and schemes to promote local manufacturing of APIs) are influencing drug pricing and supply. This tends to compress margins but increase access, and shift market share toward generic players.\u00a0<\/span>\u00a0<\/span><\/p>\n

Urbanisation, Lifestyle Changes, and Disease Burden<\/span><\/b>\u00a0<\/span><\/p>\n

The prevalence of type-2 diabetes in India is increasing, driven by urban lifestyles, dietary changes, obesity, physical inactivity etc. With more people diagnosed, demand for manageable drug therapies (especially oral ones) is increasing. This trend is pushing up prescription volumes even as average prices (for some segment) come under pressure.\u00a0<\/span>\u00a0<\/span><\/p>\n

Distribution Channels Adapting<\/span><\/b>\u00a0<\/span><\/p>\n

Hospital pharmacies remain a major channel for diabetes drugs, particularly for more expensive or novel medications or injectables. Meanwhile, online pharmacies and retail outlets are growing in importance, especially for generic or more established oral treatments. Buyers are increasingly price sensitive and sometimes willing to purchase via lower-cost channels.\u00a0<\/span>\u00a0<\/span><\/p>\n

Check out more details and stay updated with the latest industry trends, including the Japanese version for localized insights: <\/span><\/b>https:\/\/www.mordorintelligence.com\/ja\/industry-reports\/india-diabetes-drugs-market?utm_source=emailwire<\/span><\/b><\/a>\u00a0<\/span><\/p>\n

\u00a0<\/span><\/p>\n

Market Segmentation in India Diabetes Drugs Market<\/span><\/b>\u00a0<\/span><\/p>\n

Here we break down how the India diabetes drugs market is divided, what the major segments are, and what each segment is showing in terms of value, share, or growth:<\/span>\u00a0<\/span><\/p>\n